Share Price and Basic Stock Data
Last Updated: November 5, 2025, 5:18 pm
| PEG Ratio | -28.22 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Sequent Scientific Ltd operates in the pharmaceuticals sector, focusing on providing innovative solutions across various healthcare needs. As of the latest reporting, the company’s stock price stood at ₹206, with a market capitalization of ₹5,191 Cr. Revenue from operations for the fiscal year ending March 2025 reached ₹1,551 Cr, reflecting a growth trajectory from ₹1,421 Cr in FY 2023. The trailing twelve months (TTM) revenue climbed to ₹1,603 Cr, illustrating a steady increase in sales performance. Quarterly sales demonstrated fluctuations, with the highest recorded in June 2025 at ₹441 Cr, indicating a seasonal trend. In comparison, the company faced challenges in earlier quarters, such as a decline in sales to ₹333 Cr in June 2023, which was a significant drop from ₹367 Cr in March 2023. This volatility in revenue underscores the need for strategic operational adjustments to stabilize performance and enhance growth in the competitive pharmaceutical landscape.
Profitability and Efficiency Metrics
Sequent Scientific’s profitability metrics reveal a challenging landscape, with a reported net profit of ₹32 Cr for FY 2025, a recovery from the net losses of ₹122 Cr in FY 2023. Operating profit margin (OPM) improved to 10.43% for FY 2025, up from a mere 1% in FY 2023, indicating better cost management and operational efficiency. The company’s return on equity (ROE) stood at 3.21% and return on capital employed (ROCE) at 8.47%, suggesting limited returns relative to the equity base, which may concern investors. The interest coverage ratio (ICR) was recorded at 2.90x, reflecting the company’s ability to service its debt, yet it remains below the typical sector standard, hinting at financial strain. Furthermore, the cash conversion cycle (CCC) was reported at 143 days, which is on the higher side compared to industry norms, indicating potential inefficiencies in managing receivables and inventory.
Balance Sheet Strength and Financial Ratios
The balance sheet of Sequent Scientific Ltd shows a mixed picture. The total assets stood at ₹1,598 Cr, with total liabilities at ₹1,598 Cr, demonstrating a balanced structure. However, borrowings were reported at ₹481 Cr, indicating a reliance on debt financing, which could pose risks in a rising interest rate environment. Reserves grew to ₹654 Cr, offering some cushion for future investments and potential expansion. The debt-to-equity ratio was recorded at 0.63x, suggesting a moderately leveraged position. The company’s book value per share was ₹28.15, which, when compared to its price-to-book value (P/BV) ratio of 4.65x, indicates that the stock is trading at a premium relative to its book value. This premium may reflect investor confidence but also raises concerns about overvaluation, especially in light of the company’s inconsistent profitability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Sequent Scientific Ltd reveals a stable base of ownership, with promoters holding 52.61% of the equity as of March 2025. This level of promoter holding indicates a strong commitment to the company’s long-term vision. Foreign institutional investors (FIIs) accounted for 6.15%, while domestic institutional investors (DIIs) held 12.98%. The public shareholding stood at 28.10%, with a total of 1,47,320 shareholders, indicating a broad base of retail participation. However, the decline in public shareholding from 37.48% in September 2022 to the current level suggests some erosion in retail confidence. The shift in DII holdings, which increased from 2.79% in September 2022 to 12.98% in March 2025, may indicate institutional endorsement of the company’s recovery strategy, though the overall decline in public ownership could reflect caution among retail investors.
Outlook, Risks, and Final Insight
Looking ahead, Sequent Scientific Ltd faces both opportunities and challenges. On the upside, the improving operational profitability and growing reserves present a foundation for potential growth and expansion. However, risks such as high debt levels, fluctuating revenue, and a prolonged cash conversion cycle could hinder progress. The company’s ability to navigate the competitive pharmaceutical landscape while managing costs effectively will be crucial. Furthermore, the concentration of promoter holdings may lead to governance concerns among minority shareholders if strategic decisions do not align with broader investor interests. For Sequent Scientific to enhance shareholder value, it must focus on improving operational efficiencies, managing its debt prudently, and fostering transparent communication with investors to rebuild confidence. Conditional scenarios could include a successful turnaround in market sentiment leading to increased institutional investments or continued volatility in sales affecting profitability.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Sequent Scientific Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 142 Cr. | 113 | 247/84.3 | 32.4 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.63 Cr. | 1.90 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 5,019 Cr. | 461 | 479/192 | 113 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.0 Cr. | 45.9 | 92.2/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 35.8 Cr. | 24.4 | 29.1/17.0 | 37.3 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,833.71 Cr | 1,197.00 | 54.56 | 196.97 | 0.33% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 341 | 338 | 375 | 367 | 333 | 346 | 329 | 361 | 390 | 369 | 391 | 402 | 441 |
| Expenses | 339 | 335 | 365 | 370 | 341 | 331 | 307 | 329 | 348 | 330 | 356 | 355 | 389 |
| Operating Profit | 2 | 3 | 10 | -3 | -8 | 15 | 22 | 32 | 42 | 39 | 34 | 46 | 52 |
| OPM % | 1% | 1% | 3% | -1% | -2% | 4% | 7% | 9% | 11% | 11% | 9% | 12% | 12% |
| Other Income | -2 | 1 | 3 | -60 | -23 | 10 | 7 | -1 | 3 | 0 | 6 | 1 | 3 |
| Interest | 7 | 8 | 10 | 11 | 10 | 13 | 13 | 12 | 16 | 14 | 15 | 15 | 14 |
| Depreciation | 14 | 13 | 14 | 15 | 14 | 15 | 15 | 16 | 16 | 17 | 17 | 16 | 15 |
| Profit before tax | -21 | -18 | -10 | -89 | -56 | -3 | 1 | 3 | 12 | 8 | 8 | 16 | 26 |
| Tax % | -27% | -75% | -4% | 4% | -38% | 123% | -617% | 52% | 24% | 20% | 20% | 36% | 31% |
| Net Profit | -15 | -4 | -10 | -92 | -35 | -7 | 11 | 1 | 9 | 6 | 6 | 10 | 18 |
| EPS in Rs | -0.60 | -0.15 | -0.36 | -3.75 | -1.40 | -0.34 | 0.33 | -0.04 | 0.26 | 0.10 | 0.14 | 0.37 | 0.57 |
Last Updated: August 20, 2025, 3:55 am
Below is a detailed analysis of the quarterly data for Sequent Scientific Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 441.00 Cr.. The value appears strong and on an upward trend. It has increased from 402.00 Cr. (Mar 2025) to 441.00 Cr., marking an increase of 39.00 Cr..
- For Expenses, as of Jun 2025, the value is 389.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 355.00 Cr. (Mar 2025) to 389.00 Cr., marking an increase of 34.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 52.00 Cr.. The value appears strong and on an upward trend. It has increased from 46.00 Cr. (Mar 2025) to 52.00 Cr., marking an increase of 6.00 Cr..
- For OPM %, as of Jun 2025, the value is 12.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 12.00%.
- For Other Income, as of Jun 2025, the value is 3.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Mar 2025) to 3.00 Cr., marking an increase of 2.00 Cr..
- For Interest, as of Jun 2025, the value is 14.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 15.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 15.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 16.00 Cr. (Mar 2025) to 15.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 26.00 Cr.. The value appears strong and on an upward trend. It has increased from 16.00 Cr. (Mar 2025) to 26.00 Cr., marking an increase of 10.00 Cr..
- For Tax %, as of Jun 2025, the value is 31.00%. The value appears to be improving (decreasing) as expected. It has decreased from 36.00% (Mar 2025) to 31.00%, marking a decrease of 5.00%.
- For Net Profit, as of Jun 2025, the value is 18.00 Cr.. The value appears strong and on an upward trend. It has increased from 10.00 Cr. (Mar 2025) to 18.00 Cr., marking an increase of 8.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.57. The value appears strong and on an upward trend. It has increased from 0.37 (Mar 2025) to 0.57, marking an increase of 0.20.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:29 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 395 | 443 | 606 | 684 | 848 | 1,039 | 1,179 | 1,362 | 1,413 | 1,421 | 1,370 | 1,551 | 1,603 |
| Expenses | 389 | 425 | 550 | 641 | 765 | 914 | 1,009 | 1,150 | 1,303 | 1,409 | 1,308 | 1,390 | 1,431 |
| Operating Profit | 6 | 18 | 56 | 43 | 83 | 125 | 170 | 212 | 109 | 12 | 61 | 162 | 172 |
| OPM % | 2% | 4% | 9% | 6% | 10% | 12% | 14% | 16% | 8% | 1% | 4% | 10% | 11% |
| Other Income | -54 | 48 | 14 | 9 | 436 | 9 | 10 | -0 | 11 | -58 | -6 | 10 | 10 |
| Interest | 34 | 43 | 38 | 28 | 33 | 33 | 36 | 24 | 16 | 36 | 48 | 61 | 59 |
| Depreciation | 29 | 32 | 46 | 40 | 41 | 42 | 51 | 51 | 52 | 56 | 62 | 66 | 65 |
| Profit before tax | -110 | -8 | -14 | -17 | 444 | 59 | 94 | 137 | 53 | -138 | -55 | 44 | 58 |
| Tax % | 1% | 40% | 19% | -3% | 3% | 3% | 13% | 24% | 15% | -11% | -46% | 27% | |
| Net Profit | -110 | -12 | -16 | -16 | 431 | 57 | 82 | 104 | 45 | -122 | -30 | 32 | 41 |
| EPS in Rs | -8.09 | -0.70 | -0.78 | -0.57 | 17.30 | 1.97 | 2.81 | 3.84 | 1.65 | -4.86 | -1.44 | 0.87 | 1.18 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 1% | 10% | 0% | 13% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 89.09% | -33.33% | 0.00% | 2793.75% | -86.77% | 43.86% | 26.83% | -56.73% | -371.11% | 75.41% | 206.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | -122.42% | 33.33% | 2793.75% | -2880.52% | 130.63% | -17.03% | -83.56% | -314.38% | 446.52% | 131.26% |
Sequent Scientific Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 6% |
| 3 Years: | 3% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 46% |
| 5 Years: | -21% |
| 3 Years: | -19% |
| TTM: | 70% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 6% |
| 3 Years: | 14% |
| 1 Year: | 1% |
| Return on Equity | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 2% |
| 3 Years: | -3% |
| Last Year: | 3% |
Last Updated: September 5, 2025, 1:26 pm
Balance Sheet
Last Updated: July 25, 2025, 2:24 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 27 | 30 | 48 | 49 | 49 | 49 | 50 | 50 | 50 | 50 | 50 | 50 |
| Reserves | 30 | 61 | 898 | 928 | 599 | 657 | 637 | 678 | 642 | 649 | 607 | 654 |
| Borrowings | 418 | 473 | 312 | 416 | 305 | 325 | 343 | 277 | 365 | 444 | 488 | 481 |
| Other Liabilities | 148 | 343 | 265 | 503 | 380 | 346 | 424 | 381 | 378 | 374 | 389 | 412 |
| Total Liabilities | 623 | 908 | 1,523 | 1,896 | 1,332 | 1,378 | 1,454 | 1,386 | 1,435 | 1,517 | 1,534 | 1,598 |
| Fixed Assets | 238 | 474 | 586 | 684 | 476 | 498 | 577 | 536 | 564 | 605 | 592 | 586 |
| CWIP | 43 | 39 | 24 | 33 | 18 | 23 | 13 | 31 | 12 | 55 | 16 | 16 |
| Investments | 0 | 59 | 428 | 428 | 239 | 180 | 171 | 83 | 38 | 0 | 4 | 0 |
| Other Assets | 342 | 336 | 485 | 751 | 599 | 677 | 693 | 737 | 821 | 856 | 922 | 996 |
| Total Assets | 623 | 908 | 1,523 | 1,896 | 1,332 | 1,378 | 1,454 | 1,386 | 1,435 | 1,517 | 1,534 | 1,598 |
Below is a detailed analysis of the balance sheet data for Sequent Scientific Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 50.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 50.00 Cr..
- For Reserves, as of Mar 2025, the value is 654.00 Cr.. The value appears strong and on an upward trend. It has increased from 607.00 Cr. (Mar 2024) to 654.00 Cr., marking an increase of 47.00 Cr..
- For Borrowings, as of Mar 2025, the value is 481.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 488.00 Cr. (Mar 2024) to 481.00 Cr., marking a decrease of 7.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 412.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 389.00 Cr. (Mar 2024) to 412.00 Cr., marking an increase of 23.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 1,598.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,534.00 Cr. (Mar 2024) to 1,598.00 Cr., marking an increase of 64.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 586.00 Cr.. The value appears to be declining and may need further review. It has decreased from 592.00 Cr. (Mar 2024) to 586.00 Cr., marking a decrease of 6.00 Cr..
- For CWIP, as of Mar 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 16.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 4.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 4.00 Cr..
- For Other Assets, as of Mar 2025, the value is 996.00 Cr.. The value appears strong and on an upward trend. It has increased from 922.00 Cr. (Mar 2024) to 996.00 Cr., marking an increase of 74.00 Cr..
- For Total Assets, as of Mar 2025, the value is 1,598.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,534.00 Cr. (Mar 2024) to 1,598.00 Cr., marking an increase of 64.00 Cr..
Notably, the Reserves (654.00 Cr.) exceed the Borrowings (481.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -412.00 | -455.00 | -256.00 | -373.00 | -222.00 | -200.00 | -173.00 | -65.00 | -256.00 | -432.00 | -427.00 | -319.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 77 | 95 | 116 | 136 | 111 | 98 | 99 | 93 | 85 | 88 | 89 | 85 |
| Inventory Days | 175 | 153 | 164 | 165 | 125 | 134 | 132 | 139 | 160 | 152 | 166 | 173 |
| Days Payable | 198 | 147 | 175 | 208 | 127 | 141 | 133 | 119 | 119 | 107 | 121 | 115 |
| Cash Conversion Cycle | 54 | 101 | 105 | 93 | 110 | 92 | 98 | 112 | 126 | 132 | 135 | 143 |
| Working Capital Days | -162 | -111 | 65 | -25 | 20 | 33 | 29 | 51 | 54 | 46 | 30 | 70 |
| ROCE % | -4% | 8% | 2% | 1% | 40% | 9% | 12% | 16% | 6% | -3% | 0% | 8% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Small Cap Fund | 10,788,925 | 0.94 | 122.72 | 10,788,925 | 2025-04-22 17:25:21 | 0% |
| UTI Healthcare Fund | 620,305 | 0.81 | 7.06 | 620,305 | 2025-04-22 03:03:37 | 0% |
| Motilal Oswal Nifty Microcap 250 Index Fund | 132,097 | 0.24 | 1.5 | 132,097 | 2025-04-22 03:03:37 | 0% |
| ITI Pharma and Healthcare Fund | 115,796 | 0.92 | 1.32 | 115,796 | 2025-04-22 03:03:37 | 0% |
| Motilal Oswal S&P BSE Healthcare ETF | 1,244 | 0.15 | 0.01 | 1,244 | 2025-04-22 17:25:21 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 0.88 | -1.44 | -4.88 | 1.67 | 3.87 |
| Diluted EPS (Rs.) | 0.85 | -1.44 | -4.88 | 1.65 | 3.85 |
| Cash EPS (Rs.) | 3.94 | 1.28 | -2.66 | 3.87 | 6.24 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 28.15 | 28.58 | 30.04 | 29.44 | 31.26 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 28.15 | 28.58 | 30.04 | 29.44 | 31.26 |
| Revenue From Operations / Share (Rs.) | 61.98 | 54.91 | 56.97 | 56.88 | 54.82 |
| PBDIT / Share (Rs.) | 7.05 | 2.90 | 0.73 | 4.84 | 8.88 |
| PBIT / Share (Rs.) | 4.40 | 0.43 | -1.50 | 2.78 | 6.84 |
| PBT / Share (Rs.) | 1.77 | -2.19 | -5.52 | 2.15 | 5.50 |
| Net Profit / Share (Rs.) | 1.29 | -1.19 | -4.89 | 1.81 | 4.21 |
| NP After MI And SOA / Share (Rs.) | 0.87 | -1.44 | -4.86 | 1.66 | 3.84 |
| PBDIT Margin (%) | 11.37 | 5.28 | 1.29 | 8.51 | 16.18 |
| PBIT Margin (%) | 7.09 | 0.79 | -2.62 | 4.89 | 12.47 |
| PBT Margin (%) | 2.85 | -3.98 | -9.68 | 3.77 | 10.03 |
| Net Profit Margin (%) | 2.07 | -2.16 | -8.58 | 3.18 | 7.67 |
| NP After MI And SOA Margin (%) | 1.41 | -2.61 | -8.52 | 2.91 | 7.00 |
| Return on Networth / Equity (%) | 3.10 | -5.46 | -17.33 | 6.03 | 13.11 |
| Return on Capital Employeed (%) | 10.03 | 1.18 | -3.72 | 7.44 | 18.22 |
| Return On Assets (%) | 1.36 | -2.32 | -7.92 | 2.86 | 6.85 |
| Long Term Debt / Equity (X) | 0.38 | 0.21 | 0.26 | 0.17 | 0.12 |
| Total Debt / Equity (X) | 0.63 | 0.68 | 0.56 | 0.46 | 0.27 |
| Asset Turnover Ratio (%) | 0.98 | 0.89 | 0.17 | 0.17 | 0.20 |
| Current Ratio (X) | 1.73 | 1.31 | 1.50 | 1.54 | 1.55 |
| Quick Ratio (X) | 0.96 | 0.76 | 0.84 | 0.85 | 0.97 |
| Inventory Turnover Ratio (X) | 4.24 | 1.77 | 0.57 | 0.74 | 0.87 |
| Interest Coverage Ratio (X) | 2.90 | 1.50 | 0.51 | 7.62 | 9.04 |
| Interest Coverage Ratio (Post Tax) (X) | 1.61 | 0.74 | -0.61 | 3.86 | 5.65 |
| Enterprise Value (Cr.) | 3717.12 | 3313.78 | 2217.18 | 3626.83 | 6172.31 |
| EV / Net Operating Revenue (X) | 2.40 | 2.42 | 1.56 | 2.57 | 4.53 |
| EV / EBITDA (X) | 21.06 | 45.79 | 120.86 | 30.16 | 28.00 |
| MarketCap / Net Operating Revenue (X) | 2.11 | 2.10 | 1.27 | 2.35 | 4.39 |
| Price / BV (X) | 4.65 | 4.38 | 2.59 | 4.86 | 8.22 |
| Price / Net Operating Revenue (X) | 2.11 | 2.10 | 1.27 | 2.35 | 4.39 |
| EarningsYield | 0.01 | -0.01 | -0.06 | 0.01 | 0.01 |
After reviewing the key financial ratios for Sequent Scientific Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.88. This value is below the healthy minimum of 5. It has increased from -1.44 (Mar 24) to 0.88, marking an increase of 2.32.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.85. This value is below the healthy minimum of 5. It has increased from -1.44 (Mar 24) to 0.85, marking an increase of 2.29.
- For Cash EPS (Rs.), as of Mar 25, the value is 3.94. This value is within the healthy range. It has increased from 1.28 (Mar 24) to 3.94, marking an increase of 2.66.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 28.15. It has decreased from 28.58 (Mar 24) to 28.15, marking a decrease of 0.43.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 28.15. It has decreased from 28.58 (Mar 24) to 28.15, marking a decrease of 0.43.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 61.98. It has increased from 54.91 (Mar 24) to 61.98, marking an increase of 7.07.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 7.05. This value is within the healthy range. It has increased from 2.90 (Mar 24) to 7.05, marking an increase of 4.15.
- For PBIT / Share (Rs.), as of Mar 25, the value is 4.40. This value is within the healthy range. It has increased from 0.43 (Mar 24) to 4.40, marking an increase of 3.97.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.77. This value is within the healthy range. It has increased from -2.19 (Mar 24) to 1.77, marking an increase of 3.96.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.29. This value is below the healthy minimum of 2. It has increased from -1.19 (Mar 24) to 1.29, marking an increase of 2.48.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.87. This value is below the healthy minimum of 2. It has increased from -1.44 (Mar 24) to 0.87, marking an increase of 2.31.
- For PBDIT Margin (%), as of Mar 25, the value is 11.37. This value is within the healthy range. It has increased from 5.28 (Mar 24) to 11.37, marking an increase of 6.09.
- For PBIT Margin (%), as of Mar 25, the value is 7.09. This value is below the healthy minimum of 10. It has increased from 0.79 (Mar 24) to 7.09, marking an increase of 6.30.
- For PBT Margin (%), as of Mar 25, the value is 2.85. This value is below the healthy minimum of 10. It has increased from -3.98 (Mar 24) to 2.85, marking an increase of 6.83.
- For Net Profit Margin (%), as of Mar 25, the value is 2.07. This value is below the healthy minimum of 5. It has increased from -2.16 (Mar 24) to 2.07, marking an increase of 4.23.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.41. This value is below the healthy minimum of 8. It has increased from -2.61 (Mar 24) to 1.41, marking an increase of 4.02.
- For Return on Networth / Equity (%), as of Mar 25, the value is 3.10. This value is below the healthy minimum of 15. It has increased from -5.46 (Mar 24) to 3.10, marking an increase of 8.56.
- For Return on Capital Employeed (%), as of Mar 25, the value is 10.03. This value is within the healthy range. It has increased from 1.18 (Mar 24) to 10.03, marking an increase of 8.85.
- For Return On Assets (%), as of Mar 25, the value is 1.36. This value is below the healthy minimum of 5. It has increased from -2.32 (Mar 24) to 1.36, marking an increase of 3.68.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.38. This value is within the healthy range. It has increased from 0.21 (Mar 24) to 0.38, marking an increase of 0.17.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.63. This value is within the healthy range. It has decreased from 0.68 (Mar 24) to 0.63, marking a decrease of 0.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.98. It has increased from 0.89 (Mar 24) to 0.98, marking an increase of 0.09.
- For Current Ratio (X), as of Mar 25, the value is 1.73. This value is within the healthy range. It has increased from 1.31 (Mar 24) to 1.73, marking an increase of 0.42.
- For Quick Ratio (X), as of Mar 25, the value is 0.96. This value is below the healthy minimum of 1. It has increased from 0.76 (Mar 24) to 0.96, marking an increase of 0.20.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.24. This value is within the healthy range. It has increased from 1.77 (Mar 24) to 4.24, marking an increase of 2.47.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.90. This value is below the healthy minimum of 3. It has increased from 1.50 (Mar 24) to 2.90, marking an increase of 1.40.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.61. This value is below the healthy minimum of 3. It has increased from 0.74 (Mar 24) to 1.61, marking an increase of 0.87.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,717.12. It has increased from 3,313.78 (Mar 24) to 3,717.12, marking an increase of 403.34.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.40. This value is within the healthy range. It has decreased from 2.42 (Mar 24) to 2.40, marking a decrease of 0.02.
- For EV / EBITDA (X), as of Mar 25, the value is 21.06. This value exceeds the healthy maximum of 15. It has decreased from 45.79 (Mar 24) to 21.06, marking a decrease of 24.73.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.11. This value is within the healthy range. It has increased from 2.10 (Mar 24) to 2.11, marking an increase of 0.01.
- For Price / BV (X), as of Mar 25, the value is 4.65. This value exceeds the healthy maximum of 3. It has increased from 4.38 (Mar 24) to 4.65, marking an increase of 0.27.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.11. This value is within the healthy range. It has increased from 2.10 (Mar 24) to 2.11, marking an increase of 0.01.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has increased from -0.01 (Mar 24) to 0.01, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Sequent Scientific Ltd:
- Net Profit Margin: 2.07%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 10.03% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 3.1% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.61
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.96
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 183 (Industry average Stock P/E: 54.56)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.63
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.07%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 3rd Floor, Srivalli�s Corporate, Hyderabad Telangana 500033 | investorrelations@sequent.in http://www.sequent.in |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Kamal K Sharma | Chairman & Ind.Director |
| Mr. Rajaram Narayanan | Managing Director & CEO |
| Mr. Vedprakash Ragate | Executive Director |
| Mr. Gregory Andrews | Non Executive Director |
| Mr. Neeraj Bharadwaj | Non Executive Director |
| Dr. Fabian Kausche | Non Executive Director |
| Dr. Hari Babu Bodepudi | Non Executive Director |
| Mr. Milind Sarwate | Independent Director |
| Ms. Revati Kasture | Independent Director |
FAQ
What is the intrinsic value of Sequent Scientific Ltd?
Sequent Scientific Ltd's intrinsic value (as of 05 November 2025) is 134.70 which is 38.49% lower the current market price of 219.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 5,516 Cr. market cap, FY2025-2026 high/low of 232/111, reserves of ₹654 Cr, and liabilities of 1,598 Cr.
What is the Market Cap of Sequent Scientific Ltd?
The Market Cap of Sequent Scientific Ltd is 5,516 Cr..
What is the current Stock Price of Sequent Scientific Ltd as on 05 November 2025?
The current stock price of Sequent Scientific Ltd as on 05 November 2025 is 219.
What is the High / Low of Sequent Scientific Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Sequent Scientific Ltd stocks is 232/111.
What is the Stock P/E of Sequent Scientific Ltd?
The Stock P/E of Sequent Scientific Ltd is 183.
What is the Book Value of Sequent Scientific Ltd?
The Book Value of Sequent Scientific Ltd is 28.1.
What is the Dividend Yield of Sequent Scientific Ltd?
The Dividend Yield of Sequent Scientific Ltd is 0.00 %.
What is the ROCE of Sequent Scientific Ltd?
The ROCE of Sequent Scientific Ltd is 8.47 %.
What is the ROE of Sequent Scientific Ltd?
The ROE of Sequent Scientific Ltd is 3.21 %.
What is the Face Value of Sequent Scientific Ltd?
The Face Value of Sequent Scientific Ltd is 2.00.